Biomarkers of scleroderma lung disease: recent progress.
This article reviews the clinical background and significance of selected biomarkers that have been studied in relation to systemic sclerosis, or scleroderma, a devastating connective tissue disease whose morbidity and mortality are often related to pulmonary complications. Interstitial lung disease is the most common pulmonary manifestation in systemic sclerosis, and the search for a noninvasive biomarker to assess and monitor patients and their lung disease is a nascent and expending field of study. In this article, we examine the background and significance of a variety of selected biomarkers and assess their role in relation to systemic sclerosis–related interstitial lung disease.
Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 912, Charleston, SC 29425-6370, USA. hant@musc.edu
Faye N
FN
Hant
Richard M
RM
Silver
D015415:Biomarkers / Q000097:blood*; D006801:Humans; D008171:Lung Diseases / Q000097:blood* / Q000209:etiology*; D012595:Scleroderma, Systemic / Q000150:complications*
D015415:Biomarkers